Grifols S.A. [GRFS] is -47.02% lower this YTD. Is it still time to buy?

Grifols S.A. [NASDAQ: GRFS] loss -8.32% on the last trading session, reaching $5.95 price per share at the time. The company report on September 15, 2022 that GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombinant human polyclonal antibody discovery platform against biological threats of interest to the DOD.

The JPEO-CBRND awarded GigaGen this Prototype Agreement under the SPARK program, an idea incubator that fuels innovation and problem solving by providing funding for potentially transformative projects. As part of this award, GigaGen will demonstrate its platform’s capabilities by producing recombinant human hyperimmune products that target DOD-priority pathogens, including a recombinant polyclonal antibody drug designed to neutralize botulinum neurotoxins A and B, with high potency and military utility. The agreement will also allow the JPEO-CBRND to evaluate GigaGen’s platform against additional biological threats, and support functional testing, manufacturing, and clinical evaluation of recombinant polyclonal drugs that meet specific performance objectives.

Grifols S.A. represents 694.92 million in outstanding shares, while the company has a total market value of $5.57 billion with the latest information. GRFS stock price has been found in the range of $5.82 to $6.44.

If compared to the average trading volume of 1.04M shares, GRFS reached a trading volume of 4143145 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Grifols S.A. [GRFS]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GRFS shares is $14.28 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GRFS stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Grifols S.A. shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on April 08, 2022. The new note on the price target was released on November 05, 2021, representing the official price target for Grifols S.A. stock.

The Average True Range (ATR) for Grifols S.A. is set at 0.39, with the Price to Sales ratio for GRFS stock in the period of the last 12 months amounting to 1.09. The Price to Book ratio for the last quarter was 0.66, with the Price to Cash per share for the same quarter was set at 0.59.

Trading performance analysis for GRFS stock

Grifols S.A. [GRFS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -23.13. With this latest performance, GRFS shares dropped by -23.52% in over the last four-week period, additionally sinking by -49.62% over the last 6 months – not to mention a drop of -60.12% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GRFS stock in for the last two-week period is set at 20.86, with the RSI for the last a single of trading hit 14.93, and the three-weeks RSI is set at 25.17 for Grifols S.A. [GRFS]. The present Moving Average for the last 50 days of trading for this stock 8.44, while it was recorded at 6.60 for the last single week of trading, and 10.80 for the last 200 days.

Grifols S.A. [GRFS]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Grifols S.A. [GRFS] shares currently have an operating margin of +11.45 and a Gross Margin at +36.78. Grifols S.A.’s Net Margin is presently recorded at +3.71.

Return on Total Capital for GRFS is now 3.63, given the latest momentum, and Return on Invested Capital for the company is 1.48. Return on Equity for this stock inclined to 3.26, with Return on Assets sitting at 1.06. When it comes to the capital structure of this company, Grifols S.A. [GRFS] has a Total Debt to Total Equity ratio set at 152.94. Additionally, GRFS Total Debt to Total Capital is recorded at 60.47, with Total Debt to Total Assets ending up at 48.28. Long-Term Debt to Equity for the company is recorded at 113.67, with the Long-Term Debt to Total Capital now at 44.94.

Reflecting on the efficiency of the workforce at the company, Grifols S.A. [GRFS] managed to generate an average of $7,864 per employee. Receivables Turnover for the company is 9.87 with a Total Asset Turnover recorded at a value of 0.29.Grifols S.A.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 2.70.

Grifols S.A. [GRFS]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GRFS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Grifols S.A. go to 13.60%.

An analysis of insider ownership at Grifols S.A. [GRFS]

Positions in Grifols S.A. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 68 institutional holders increased their position in Grifols S.A. [NASDAQ:GRFS] by around 13,406,851 shares. Additionally, 63 investors decreased positions by around 8,650,545 shares, while 22 investors held positions by with 83,048,502 shares. The mentioned changes placed institutional holdings at 105,105,898 shares, according to the latest SEC report filing. GRFS stock had 20 new institutional investments in for a total of 1,247,812 shares, while 17 institutional investors sold positions of 1,662,416 shares during the same period.


Please enter your comment!
Please enter your name here